Trigeminal autonomic cephalalgias (TACs) are a group of primary headache disorders that are characterized by attacks of unilateral pain of varying duration and prominent, ipsilateral cranial autonomic symptoms, such as lacrimation, conjunctival injection, nasal congestion, rhinorrhea, or periorbital edema. The TACs include cluster headaches, paroxysmal hemicrania, hemicrania continua, and short-lasting unilateral neuralgiform headache attacks with conjunctival injection and tearing or cranial autonomic symptoms. Results | Fifteen patients were identified ( Figure) , and 9 (60%) had HC (6 women) while 6 (40%) had PH (5 women). The mean (SD) age was 43 (11) years. Noninvasive vagus nerve stimulation was the primary treatment for 10 patients (7 HC, 3 PH) who could not tolerate indomethacin and was used as adjunctive therapy at the maximum tolerated dose (range, 50-225 mg daily) of oral indomethacin for 5 patients (2 HC, 3 PH).
Among patients with HC, 7 (78%) reported experiencing a reduced severity of continuous pain. Two patients reported experiencing a reduced frequency of exacerbations and a reduced severity and duration of exacerbations with acute treatment. A third reported experiencing a reduced duration of exacerbations. Among patients with PH, 4 (67%) reported receiving benefits from treatment. One patient with PH became attack-free, and among the other 3 patients, 2 reported experiencing a reduced attack frequency, 3 reduced severity, and 1 shorter duration (Table) . Effective dosing regimens ranged from 2 to 4 doses twice daily or 2 to 3 doses 3 times daily. The duration of use at last follow-up ranged from 3 months to 5 years.
Discussion | The GammaCore generates a 120-second electrical impulse of adjustable amplitude that stimulates the cervical branch of the vagus nerve when held against the neck. Patients were typically advised to begin with two 120-second doses that were applied ipsilateral to pain twice daily, with the dose titration based on effect and tolerability. Most patients judged nVNS treatment to be useful. However, with the exception of 1 patient (17%) with PH, none of the patients became pain-free.
Whereas all patients in this series experienced prohibitive or dose-limiting adverse effects from indomethacin, only 1 (7%) needed to reduce the nVNS dose (from 10 to 6 daily doses for HC) because of cutaneous irritation at the stimulation site. Our initial experience suggests that nVNS may be an important alternative or adjunctive therapy for patients with these indomethacin-sensitive TACs who are unable to tolerate indomethacin. Conducting a prospective, randomized, and sham-controlled study seems warranted, although given the rarity of the problem, this will be a considerable challenge.
